275 related articles for article (PubMed ID: 12895211)
1. Review article: mild to moderate Crohn's disease--defining the basis for a new treatment algorithm.
Sandborn WJ; Feagan BG
Aliment Pharmacol Ther; 2003 Aug; 18(3):263-77. PubMed ID: 12895211
[TBL] [Abstract][Full Text] [Related]
2. Aminosalicylates for induction of remission or response in Crohn's disease.
Lim WC; Wang Y; MacDonald JK; Hanauer S
Cochrane Database Syst Rev; 2016 Jul; 7(7):CD008870. PubMed ID: 27372735
[TBL] [Abstract][Full Text] [Related]
3. Aminosalicylates for induction of remission or response in Crohn's disease.
Lim WC; Hanauer S
Cochrane Database Syst Rev; 2010 Dec; (12):CD008870. PubMed ID: 21154400
[TBL] [Abstract][Full Text] [Related]
4. Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn's Disease: A Bayesian Network Meta-analysis.
Coward S; Kuenzig ME; Hazlewood G; Clement F; McBrien K; Holmes R; Panaccione R; Ghosh S; Seow CH; Rezaie A; Kaplan GG
Inflamm Bowel Dis; 2017 Mar; 23(3):461-472. PubMed ID: 28146003
[TBL] [Abstract][Full Text] [Related]
5. Initial therapy for mild to moderate Crohn's disease: mesalamine or budesonide?
Feagan BG; Sandborn WJ
Rev Gastroenterol Disord; 2002; 2 Suppl 2():S9-15. PubMed ID: 12478239
[TBL] [Abstract][Full Text] [Related]
6. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.
Thomsen OO; Cortot A; Jewell D; Wright JP; Winter T; Veloso FT; Vatn M; Persson T; Pettersson E
N Engl J Med; 1998 Aug; 339(6):370-4. PubMed ID: 9691103
[TBL] [Abstract][Full Text] [Related]
7. Budesonide for induction of remission in Crohn's disease.
Otley A; Steinhart AH
Cochrane Database Syst Rev; 2005 Oct; (4):CD000296. PubMed ID: 16235274
[TBL] [Abstract][Full Text] [Related]
8. The effectiveness of budesonide therapy for Crohn's disease.
Kane SV; Schoenfeld P; Sandborn WJ; Tremaine W; Hofer T; Feagan BG
Aliment Pharmacol Ther; 2002 Aug; 16(8):1509-17. PubMed ID: 12182751
[TBL] [Abstract][Full Text] [Related]
9. Medical management of mild to moderate Crohn's disease: evidence-based treatment algorithms for induction and maintenance of remission.
Sandborn WJ; Feagan BG; Lichtenstein GR
Aliment Pharmacol Ther; 2007 Oct; 26(7):987-1003. PubMed ID: 17877506
[TBL] [Abstract][Full Text] [Related]
10. Budesonide led to a greater remission rate and fewer severe adverse events than did mesalamine in Crohn's disease.
Rutgeerts P
Gut; 1999 Jul; 45(1):13-4. PubMed ID: 10498451
[No Abstract] [Full Text] [Related]
11. Comparative Effectiveness of Mesalamine, Sulfasalazine, Corticosteroids, and Budesonide for the Induction of Remission in Crohn's Disease: A Bayesian Network Meta-analysis: Republished.
Coward S; Kuenzig ME; Hazlewood G; Clement F; McBrien K; Holmes R; Panaccione R; Ghosh S; Seow CH; Rezaie A; Kaplan GG
Inflamm Bowel Dis; 2017 May; 23(5):E26-E37. PubMed ID: 30052985
[TBL] [Abstract][Full Text] [Related]
12. Conventional treatment of Crohn's disease: objectives and outcomes.
Rutgeerts PJ
Inflamm Bowel Dis; 2001 May; 7 Suppl 1():S2-8. PubMed ID: 11380039
[TBL] [Abstract][Full Text] [Related]
13. Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease.
Mantzaris GJ; Petraki K; Sfakianakis M; Archavlis E; Christidou A; Chadio-Iordanides H; Triadaphyllou G
Clin Gastroenterol Hepatol; 2003 Mar; 1(2):122-8. PubMed ID: 15017504
[TBL] [Abstract][Full Text] [Related]
14. Medical management of Crohn's disease.
Cottone M; Renna S; Orlando A; Mocciaro F
Expert Opin Pharmacother; 2011 Nov; 12(16):2505-25. PubMed ID: 21988215
[TBL] [Abstract][Full Text] [Related]
15. Mild to moderate Crohn's disease: an evidence-based treatment algorithm.
Wong K; Bressler B
Drugs; 2008; 68(17):2419-25. PubMed ID: 19016571
[TBL] [Abstract][Full Text] [Related]
16. Update on the management of Crohn's disease.
Buchner AM; Blonski W; Lichtenstein GR
Curr Gastroenterol Rep; 2011 Oct; 13(5):465-74. PubMed ID: 21792543
[TBL] [Abstract][Full Text] [Related]
17. Budesonide in the treatment of Crohn's disease: a meta-analysis.
Papi C; Luchetti R; Gili L; Montanti S; Koch M; Capurso L
Aliment Pharmacol Ther; 2000 Nov; 14(11):1419-28. PubMed ID: 11069312
[TBL] [Abstract][Full Text] [Related]
18. Budesonide (Entocort EC Capsules): a review of its therapeutic use in the management of active Crohn's disease in adults.
McKeage K; Goa KL
Drugs; 2002; 62(15):2263-82. PubMed ID: 12381231
[TBL] [Abstract][Full Text] [Related]
19. Budesonide and mesalazine in active Crohn's disease: a comparison of the effects on quality of life.
Thomsen OO; Cortot A; Jewell D; Wright JP; Winter T; Veloso FT; Vatn M; Persson T; Pettersson E;
Am J Gastroenterol; 2002 Mar; 97(3):649-53. PubMed ID: 11922560
[TBL] [Abstract][Full Text] [Related]
20. Budesonide for induction of remission in Crohn's disease.
Seow CH; Benchimol EI; Griffiths AM; Otley AR; Steinhart AH
Cochrane Database Syst Rev; 2008 Jul; (3):CD000296. PubMed ID: 18646064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
